ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. PROK's Phase 3 PROACT 1 study uses eGFR slope as a surrogate endpoint, with topline data expected in Q2 2027 and potential for accelerated approval. The company halted its second Phase 3 trial, saving over $150m, and expects positive REGEN-007 results to be presented at ASN Kidney Week in November.
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
PROKIDNEY CP (PROK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
Does ProKidney Corp. (PROK) have what it takes to be a top stock pick for momentum investors? Let's find out.
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.
ProKidney: What's Happening With PROK Stock?
ProKidney Corp. (NASDAQ: PROK) has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study, which assesses rilparencel in patients suffering from chronic kidney disease (CKD) and diabetes. The study indicated considerable enhancements in kidney function:
ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying
The stock of the day on Tuesday was ProKidney Corp.'s, as it was both the biggest gainer and the most actively traded on major U.S. exchanges, after the biotechnology company's diabetes treatment produced positive results in a mid-stage trial.
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Rilparencel is ProKidney's main candidate. It is intended as a therapy that stabilizes kidneys, making it potentially useful for CKD patients. We'll have Rilparencel's Phase 2 full data in 2025, as well as the potential confirmation about a “surrogate” endpoint for its Phase 3 trials. Currently, Rilparencel's Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that's suitable for the FDA.
